- Home
- LUCY vs NCNA Comparison
LUCY vs NCNA Comparison
Compare LUCY & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | NCNA |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.6M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LUCY | NCNA |
|---|---|---|
| Price | $1.48 | $4.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 64.5K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,392,547.00 | N/A |
| Revenue This Year | $80.76 | N/A |
| Revenue Next Year | $210.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.22 | N/A |
| 52 Week Low | $1.29 | $2.78 |
| 52 Week High | $7.60 | $330.00 |
Technical Indicators
Market Signals| Indicator | LUCY | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 60.10 |
| Support Level | $1.53 | $3.82 |
| Resistance Level | $1.72 | $4.35 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 44.19 | 95.99 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.